Strategic Initiative

Slingshot members are tracking this corporate initiative:

Catalyst Pharma (CPRX) Announces Collaboration to Offer Biocept's (BIOC) Target Selector Platform in Phase 3 Study Evaluating Firdapse in Patients with Lambert Eaton Myasthenic Syndrome (LEMS)

Source Link:: http://www.prnewswire.com/news-releases/biocept-and-catalyst-pharmaceuticals-collaborate-to-provide-liquid-biopsy-testing-for-small-cell-lung-cancer-to-patients-with-lambert-eaton-myasthenic-syndrome-lems-300423068.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CPRX

100%

BIOC

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Mar 14, 2017

Projected Implementation:

Q2, 2017

Relevance Tracked Until:

Q2, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Collaboration, Target Selector Platform, Phase 3, Firdapse, Lambert-eaton Myasthenic Syndrome